nipocalimab

News

J&J gets EU approval for Imaavy in gMG

J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis.

News

J&J's 'Swiss army knife' drug gets first FDA approval

Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).

News

J&J's nipocalimab fast-tracked for Sjogren's disease

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.

News

J&J launches gMG market bid with nipocalimab filing

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit

News

J&J adds another string to nipocalimab bow with gMG data

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drug

News

J&J’s nipocalimab raises hope for Sjogren’s patients

Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects million

J&J gets EU approval for Imaavy in gMG

J&J's 'Swiss army knife' drug gets first FDA approval

J&J's nipocalimab fast-tracked for Sjogren's disease

J&J launches gMG market bid with nipocalimab filing

J&J adds another string to nipocalimab bow with gMG data

J&J’s nipocalimab raises hope for Sjogren’s patients

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

nipocalimab

Editor's Picks